Osimertinib May Be Beneficial for NSCLC Patients With Intracranial Metastasis Osimertinib May Be Beneficial for NSCLC Patients With Intracranial Metastasis
Results of a systematic review and meta-analysis support a possible role for osimertinib in the management of non-small-cell lung cancer (NSCLC) patients with intracranial metastatic disease, researchers say.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
More News: Cancer | Cancer & Oncology | Health | Hematology | Lung Cancer | Non-Small Cell Lung Cancer